S
Steven D. Chernausek
Researcher at University of Oklahoma Health Sciences Center
Publications - 116
Citations - 6404
Steven D. Chernausek is an academic researcher from University of Oklahoma Health Sciences Center. The author has contributed to research in topics: Short stature & Growth factor. The author has an hindex of 34, co-authored 108 publications receiving 5862 citations. Previous affiliations of Steven D. Chernausek include Cincinnati Children's Hospital Medical Center & Hamm AG.
Papers
More filters
Journal ArticleDOI
Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop
Pinchas Cohen,Alan D. Rogol,Cheri Deal,Paul Saenger,Edward O. Reiter,Judith L. Ross,Steven D. Chernausek,M.O. Savage,Jan M. Wit +8 more
TL;DR: GH therapy for children with ISS has a similar safety profile to other GH indications, and psychological counseling is worthwhile to consider instead of or as an adjunct to hormone treatment.
Journal ArticleDOI
IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation
M. Jennifer Abuzzahab,Anke Schneider,Audrey Goddard,Florin Grigorescu,Corinne Lautier,Eberhard Keller,Wieland Kiess,Jürgen Klammt,Jürgen Kratzsch,Doreen Osgood,Roland Pfäffle,Klemens Raile,Berthold Seidel,Robert J. Smith,Steven D. Chernausek +14 more
TL;DR: Mutations in the IGF-IR gene that lead to abnormalities in the function or number of IGF-I receptors may also retard intrauterine and subsequent growth in humans.
Journal ArticleDOI
International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001
TL;DR: The objectives of GH therapy in short children who are SGA are catch-up growth in early childhood, maintenance of normal growth in childhood, and achievement of normal adult height.
Journal ArticleDOI
Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation.
Guisheng Zhao,Marie Claude Monier-Faugere,M.C. Langub,Zhaopo Geng,Toshiyuki Nakayama,J. Wesley Pike,Steven D. Chernausek,Clifford J. Rosen,L.R. Donahue,Hartmut H. Malluche,James A. Fagin,Thomas L. Clemens,Thomas L. Clemens +12 more
TL;DR: It is concluded that IGF-I produced locally in bone osteoblasts exerts its anabolic effect primarily by increasing the activity of resident osteoblasting in transgenic mice.
Journal ArticleDOI
Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
TL;DR: Treatment with rhIGF-I stimulates linear growth in children with severe IGF-I deficiency due to GH insensitivity, and adverse events are common but are rarely of sufficient severity to interrupt or modify treatment.